BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37067547)

  • 21. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.
    Edwards BK; Noone AM; Mariotto AB; Simard EP; Boscoe FP; Henley SJ; Jemal A; Cho H; Anderson RN; Kohler BA; Eheman CR; Ward EM
    Cancer; 2014 May; 120(9):1290-314. PubMed ID: 24343171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
    Amadou A; Freisling H; Jenab M; Tsilidis KK; Trichopoulou A; Boffetta P; Van Guelpen B; Mokoroa O; Wilsgaard T; Kee F; Schöttker B; Ordóñez-Mena JM; Männistö S; Söderberg S; Vermeulen RCH; Quirós JR; Liao LM; Sinha R; Kuulasmaa K; Brenner H; Romieu I
    Br J Cancer; 2021 May; 124(11):1882-1890. PubMed ID: 33772152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    Abhyankar N; Hoskins KF; Abern MR; Calip GS
    BMC Cancer; 2017 Sep; 17(1):659. PubMed ID: 28946846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone therapy in prostate cancer: is it still a controversy?
    Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
    Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers.
    Feng X; Higa GM; Safarudin F; Sambamoorthi U; Tan X
    J Geriatr Oncol; 2019 Sep; 10(5):698-704. PubMed ID: 30772191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
    Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
    JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
    Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
    Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.
    Resnick MJ; Graves AJ; Gambrel RJ; Thapa S; Buntin MB; Penson DF
    Cancer; 2018 Nov; 124(22):4366-4373. PubMed ID: 30412287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer stage at diagnosis and survival among persons with Social Security Disability Insurance on Medicare.
    McCarthy EP; Ngo LH; Chirikos TN; Roetzheim RG; Li D; Drews RE; Iezzoni LI
    Health Serv Res; 2007 Apr; 42(2):611-28. PubMed ID: 17362209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts.
    Cardwell CR; Mc Menamin ÚC; Hicks BM; Hughes C; Cantwell MM; Murray LJ
    BMC Med; 2014 Feb; 12():28. PubMed ID: 24521426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Family history of hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario.
    Jang JH; Cotterchio M; Gallinger S; Knight JA; Daftary D
    Int J Cancer; 2009 Aug; 125(4):918-25. PubMed ID: 19437533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.
    Heath AK; Hodge AM; Ebeling PR; Eyles DW; Kvaskoff D; Buchanan DD; Giles GG; Williamson EJ; English DR
    Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):900-908. PubMed ID: 30842127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.
    Gillessen S; Templeton A; Marra G; Kuo YF; Valtorta E; Shahinian VB
    J Natl Cancer Inst; 2010 Dec; 102(23):1760-70. PubMed ID: 21068432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
    Kenfield SA; DuPre N; Richman EL; Stampfer MJ; Chan JM; Giovannucci EL
    Eur Urol; 2014 May; 65(5):887-94. PubMed ID: 23962747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary care utilization and colorectal cancer incidence and mortality among Medicare beneficiaries: a population-based, case-control study.
    Ferrante JM; Lee JH; McCarthy EP; Fisher KJ; Chen R; Gonzalez EC; Love-Jackson K; Roetzheim RG
    Ann Intern Med; 2013 Oct; 159(7):437-446. PubMed ID: 24081284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP Diet and Health Study.
    Kelly SP; Lennon H; Sperrin M; Matthews C; Freedman ND; Albanes D; Leitzmann MF; Renehan AG; Cook MB
    Int J Epidemiol; 2019 Apr; 48(2):464-473. PubMed ID: 30376043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled sample-based GWAS: a cost-effective alternative for identifying colorectal and prostate cancer risk variants in the Polish population.
    Gaj P; Maryan N; Hennig EE; Ledwon JK; Paziewska A; Majewska A; Karczmarski J; Nesteruk M; Wolski J; Antoniewicz AA; Przytulski K; Rutkowski A; Teumer A; Homuth G; Starzyńska T; Regula J; Ostrowski J
    PLoS One; 2012; 7(4):e35307. PubMed ID: 22532847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer.
    Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
    J Geriatr Oncol; 2019 Sep; 10(5):705-708. PubMed ID: 30795923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.